Type 1 Diabetes (T1D): Clinical Trials

3 trials for Type 1 Diabetes (T1D), newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 recruiting, 1 not yet recruiting. 3 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 33Recruiting 2, Not yet recruiting 1

Follow Type 1 Diabetes (T1D): new trials by email Literature Review of Type 1 Diabetes (T1D) trials Research Report on Type 1 Diabetes (T1D)

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
CKM For Safe Use of SGLT2i in Type 1 Diabetes
Sotagliflozin Low Dose, Sotagliflozin High Dose, Dual Continuous Glucose and Ketone Monitor - Type 1 Diabetes (T1D)
Phase 3Not yet recruitingUniversity of California, San Diego522027-04-012026-11-04
PRISE (Personalized Response and Immunologic Surveillance of Endogenous C-Peptide Preservation in New, Recent, and Established Onset Type 1 Diabetes Treated With Human Anti-Thymocyte Globulin [h-ATG]) Study
SAB-142, Placebo - Type 1 Diabetes (T1D)
Phase 3RecruitingUniversity of Florida1082026-11-102026-11-16
GIP/GLP-1RA as Adjunctive to Automated Insulin Delivery in Adults With Type 1 Diabetes
Tirzepatide - Type 1 Diabetes (T1D)
Phase 3RecruitingUniversity of Bern422025-02-142026-01-26

Narrower conditions

Diabetes Mellitus, Type 1 (3)

Broader conditions

Autoimmune Diseases (3)  ·  Diabetes Mellitus (3)  ·  Endocrine System Diseases (3)  ·  Glucose Metabolism Disorders (3)  ·  Immune System Diseases (3)  ·  Metabolic Diseases (3)  ·  Nutritional and Metabolic Diseases (3)

Interventions

(2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol (1)  ·  Tirzepatide (1)

Sponsors

University of Bern (1)  ·  University of California, San Diego (1)  ·  University of Florida (1)

Countries

United States (2)  ·  Switzerland (1)

Top investigators

Thomas Zueger, PD Dr. med. (1)

NIH funding

2025 (1), U01DK143381 (1)